Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete ELEMENT--Back to the Newsroom# NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is CompleteSHELTON, CT / ACCESS Newswire/ March 11, 2026 / NanoViricides, Inc. (AMEX: NNVC) (the "Company"), a clinical s ...

Core Viewpoint - NanoViricides is advancing its broad-spectrum antiviral candidate NV-387, focusing on Mpox clinical development and confirming orphan drug designation filings for multiple indications [1] Company Progress - The company has completed the full clinical trial application to initiate a Phase 2 study of NV-387 in the Democratic Republic of Congo for Mpox, with import permissions secured [2][6] - The Phase 2 study is fully funded, with approximately $5.5 million raised in November and a quarterly spend of about $1.8 million [3][7] Market Context - Despite the WHO lifting the global Public Health Emergency declaration, Mpox cases continue to rise in parts of Africa, indicating a persistent need for development [3][5] - The focus on Mpox was chosen due to its shorter development pathway compared to other diseases like RSV and influenza, which require longer trials [8] Orphan Drug Designation - The company is filing for orphan drug designation for NV-387, which could lead to quicker regulatory approvals and significant benefits such as R&D tax credits and marketing exclusivity [9][11] - Orphan drug designation applications are typically processed within three to four months, and if granted, could allow for accelerated approval after Phase 2 trials [11][12] Potential Market Impact - The drug targets significant markets, including smallpox, Mpox, and measles, with rising measles cases in the US highlighting the need for effective treatments [10]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Financial Performance - The company reported a net loss per common share for the three months ended December 31, 2025, with basic and diluted EPS reflecting the loss due to anti-dilutive shares[34][36]. - The company has 7,148,006 potentially dilutive common shares excluded from the diluted net loss per common share calculation for the three months ended December 31, 2025[37]. - The company accrued expenses totaled $48,380 as of December 31, 2025, compared to $25,969 as of June 30, 2025, indicating an increase in personnel and compensation costs[54]. Assets and Liabilities - As of December 31, 2025, the total property and equipment net value was $6,656,439, a decrease from $6,833,891 as of June 30, 2025, reflecting a depreciation expense of $131,016 for the three months ended December 31, 2025[52]. - The net intangible assets as of December 31, 2025, amounted to $312,904, down from $317,039 as of June 30, 2025, with an amortization expense of $2,068 for the three months ended December 31, 2025[53]. - The accounts payable to TheraCour as of December 31, 2025, was $691,865, reflecting ongoing obligations under licensing agreements[46]. - The company has not drawn against the $3,000,000 line of credit facility established with Dr. Anil R. Diwan as of December 31, 2025[51]. Research and Development - The company incurred research and development costs related to related parties amounting to $485,792 for the three months ended December 31, 2025[46]. - The Phase 1 human clinical trial of NV-CoV-2 began in India on June 17, 2023, under an agreement with KMPL[46]. - The company accrued clinical trial costs related to the Phase 1a/1b trials in India, amounting to $9,932 as of June 30, 2025[47]. Capital Raising Activities - The company raised approximately $1,909,000 in net proceeds from the ATM offering by selling 1,264,988 shares at an average price of $1.56 per share from July 1, 2025, to December 31, 2025[55]. - In a registered direct offering on November 10, 2025, the company sold 1,970,000 shares at an offering price of $1.68 per share, generating gross proceeds of $6,000,000 and net proceeds of $5,403,981 after expenses[59]. Stock and Compensation - The company granted Dr. Anil Diwan 10,204 shares of Series A preferred stock, with a non-cash compensation expense of $20,026 recognized for the six months ended December 31, 2025[63]. - The company issued 19,255 fully vested shares of common stock for consulting services, recording an expense of $27,000 for the three months ended December 31, 2025[68]. - As of December 31, 2025, the company had 7,148,006 outstanding and exercisable common stock warrants with a weighted average exercise price of $1.88 per share[70]. Legal and Regulatory Matters - The company has no pending legal proceedings that it believes will have a material adverse effect on its business or financial position[71]. - The Company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[351]. Licensing Agreements - The company is dependent on its license agreements with TheraCour for the development of its drug candidates, which could incur substantial delays and costs if lost[74]. - The Company entered into a license agreement with KMPL for exclusive rights to use, sell, or offer two clinical test drug candidates for COVID treatment in India[76]. - KMPL will receive a clinical trials manager fee of 30% of the costs and applicable taxes, and a 70% royalty on commercial sales of approved drugs[76]. - An amendment to the COVID License Agreement with TheraCour stipulates that cash milestone payments will only be payable upon the Company achieving sufficient revenues[77]. - A Memorandum of Understanding with TheraCour grants the Company a right of first refusal for licensing any antiviral drugs in development for research and development purposes[78]. - The MoU codifies the treatment of future milestone payments to be consistent with the principles established in the February 12, 2024 amendment[78]. Accounting Standards - The company adopted ASU 2023-07 for segment reporting, effective January 1, 2024, which requires enhanced disclosures regarding segment expenses[41]. - The company expects the adoption of ASU 2024-03 to have minimal impact on its financial statements, effective for fiscal years beginning after December 15, 2026[40].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Viewpoint - NanoViricides, Inc. has filed for Orphan Drug Designation for NV-387 as a treatment for Measles with the US FDA, which could provide significant incentives if approved [1] Group 1: Company Developments - The company is a clinical stage leader in developing broad-spectrum antivirals using host-mimetic nanomedicine technology [1] - The application for Orphan Drug Designation (ODD) is aimed at enhancing the treatment options for Measles [1] Group 2: Regulatory Incentives - If granted, the orphan drug designation will provide the company with tax credits for qualified clinical trials [1] - The designation will exempt the company from certain user fees [1] - The company could gain potential market exclusivity for seven years post-approval [1]

Company Overview - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance workflows and improve content delivery [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - The current severe influenza wave highlights the urgent need for broad-spectrum antivirals that can effectively target all influenza viruses and other seasonal respiratory viruses, including RSV and Coronaviruses [1] Company Summary - NanoViricides, Inc. is positioned as a clinical stage leader in the development of innovative broad-spectrum antiviral drugs that are designed to be effective against viruses [1] - The company emphasizes the significance of its antiviral solutions in light of the CDC's classification of this year's flu season as "moderately severe" [1]